Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients (IF=0.6)









 中文 EN

ACADEMIC HISKY

MAFLD Assessment of liver health Viral hepatitis Liver Cancer and Cirrhosis Evaluate the efficacy of medication Others

Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients (IF=0.6)

Hong Deng, ZhiLiang Gao, et al. Hepat Mon. 2016 September, 16(9), e40263.

Objective

•To evaluate the diagnostic performance of the fat attenuation parameter (FAP) measured by FibroTouch.
•A new algorithm to assess hepatic steatosis in CHB patients, in comparison to liver biopsy.

Methods

•The performances of FAP and fatty index were assessed by AUROC.
•254 CHB patients underwent simultaneous liver biopsy, biochemical blood testing, FibroTouch examination.
•A new algorithm based on four factors (FAP; body mass index, BMI; high-density lipoprotein, HDL; apolipoprotein B, APOB) was defined as follows: fatty index=10*ep/ (1 + ep), and P = -2.75 + 0.028 ln FAP (dB/m) + 0.409 ln BMI (Kg/m2)-2.482 ln HDL (mmol/L) + 1.979 ln APOB (g/L).

Figures & Tables

Results

•The difference in FAP was significant (P < 0.001) between CHB-only patients and CHB patients with hepatic steatosis.
•The optimal cutoff FAP values for hepatic steatosis of > 0, 5%, 10%, 20%, and 30% were 224.1, 230.6, 235.5, 246.9, and 261.1 dB/m, and AUROCs were 0.833, 0.801, 0.915, 0.917, and 0.972,
espectively. The optimal cutoff value of fatty index for the diagnosis of hepatic steatosis was 1.5 and the AUROC was 0.807.

Conclusion

•FAP is an accurate, reliable, and noninvasive approach that can also be combined with other metabolic biomarkers to comprehensively detect and quantify hepatic steatosis.

If you need more academic materials, please contact us.